New drug targets immune system to tame arthritis
Disease control
Recruiting now
This early-stage trial tests a new medicine called SR-878 in 27 adults with rheumatoid arthritis. The drug works by blocking a protein that controls immune signals. The main goal is to check safety and find a good dose. Participants will be followed for about 16 weeks.
Phase: PHASE1 • Sponsor: SciRhom GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC